Cargando…

Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis

Pseudomonas infection is a major determinant of morbidity and mortality in cystic fibrosis (CF). Maintaining optimal lung function in CF patients carrying Pseudomonas remains a challenge. Our study aims to investigate the efficacy of antipseudomonal inhaled antibiotics in CF patients with chronic Ps...

Descripción completa

Detalles Bibliográficos
Autores principales: Varannai, Orsolya, Gede, Noémi, Juhász, Márk Félix, Szakács, Zsolt, Dembrovszky, Fanni, Németh, Dávid, Hegyi, Péter, Párniczky, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388982/
https://www.ncbi.nlm.nih.gov/pubmed/34438986
http://dx.doi.org/10.3390/antibiotics10080936
_version_ 1783742758102499328
author Varannai, Orsolya
Gede, Noémi
Juhász, Márk Félix
Szakács, Zsolt
Dembrovszky, Fanni
Németh, Dávid
Hegyi, Péter
Párniczky, Andrea
author_facet Varannai, Orsolya
Gede, Noémi
Juhász, Márk Félix
Szakács, Zsolt
Dembrovszky, Fanni
Németh, Dávid
Hegyi, Péter
Párniczky, Andrea
author_sort Varannai, Orsolya
collection PubMed
description Pseudomonas infection is a major determinant of morbidity and mortality in cystic fibrosis (CF). Maintaining optimal lung function in CF patients carrying Pseudomonas remains a challenge. Our study aims to investigate the efficacy of antipseudomonal inhaled antibiotics in CF patients with chronic Pseudomonas infection. A Bayesian network meta-analysis of randomized controlled trials was conducted. The main outcomes were changes in: (a) forced respiratory volume (FEV1), (b) Pseudomonas aeruginosa sputum density, and (c) CF Questionnaire Revised Respiratory Symptom Score (CFQR-RSS) at 4 weeks follow-up. Eighteen trials which reported on treatment with aztreonam lysine, tobramycin, colistin, levofloxacin, fosfomycin/tobramycin, and amikacin in various dosages were eligible for inclusion. In terms of change in FEV1%, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 77, 76%, respectively). Regarding change in Pseudomonas sputum density, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 90, 86%, respectively). Regarding change in CFQR-RSS, aztreonam lysine (t.i.d., 75 mg) and aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin inhalation solution phase had the highest probability of being the most effective treatments (SUCRA:74% and 72%, respectively). Regarding changes in FEV1% and Pseudomonas sputum density, aztreonam lysine with a run in tobramycin phase may be the best treatment option in treating chronic Pseudomonas in CF. According to CFQR-RSS no significant differences were found. Given the limitations of the studies included, validation trials are called for.
format Online
Article
Text
id pubmed-8388982
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83889822021-08-27 Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis Varannai, Orsolya Gede, Noémi Juhász, Márk Félix Szakács, Zsolt Dembrovszky, Fanni Németh, Dávid Hegyi, Péter Párniczky, Andrea Antibiotics (Basel) Article Pseudomonas infection is a major determinant of morbidity and mortality in cystic fibrosis (CF). Maintaining optimal lung function in CF patients carrying Pseudomonas remains a challenge. Our study aims to investigate the efficacy of antipseudomonal inhaled antibiotics in CF patients with chronic Pseudomonas infection. A Bayesian network meta-analysis of randomized controlled trials was conducted. The main outcomes were changes in: (a) forced respiratory volume (FEV1), (b) Pseudomonas aeruginosa sputum density, and (c) CF Questionnaire Revised Respiratory Symptom Score (CFQR-RSS) at 4 weeks follow-up. Eighteen trials which reported on treatment with aztreonam lysine, tobramycin, colistin, levofloxacin, fosfomycin/tobramycin, and amikacin in various dosages were eligible for inclusion. In terms of change in FEV1%, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 77, 76%, respectively). Regarding change in Pseudomonas sputum density, aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin phase, aztreonam lysine (t.i.d., 75 mg) with a 28-day run in the tobramycin phase had the highest probability of being the most effective treatment (SUCRAs were 90, 86%, respectively). Regarding change in CFQR-RSS, aztreonam lysine (t.i.d., 75 mg) and aztreonam lysine (b.i.d., 75 mg) with a 28-day run in the tobramycin inhalation solution phase had the highest probability of being the most effective treatments (SUCRA:74% and 72%, respectively). Regarding changes in FEV1% and Pseudomonas sputum density, aztreonam lysine with a run in tobramycin phase may be the best treatment option in treating chronic Pseudomonas in CF. According to CFQR-RSS no significant differences were found. Given the limitations of the studies included, validation trials are called for. MDPI 2021-08-03 /pmc/articles/PMC8388982/ /pubmed/34438986 http://dx.doi.org/10.3390/antibiotics10080936 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Varannai, Orsolya
Gede, Noémi
Juhász, Márk Félix
Szakács, Zsolt
Dembrovszky, Fanni
Németh, Dávid
Hegyi, Péter
Párniczky, Andrea
Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
title Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
title_full Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
title_fullStr Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
title_full_unstemmed Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
title_short Therapeutic Approach of Chronic Pseudomonas Infection in Cystic Fibrosis—A Network Meta-Analysis
title_sort therapeutic approach of chronic pseudomonas infection in cystic fibrosis—a network meta-analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8388982/
https://www.ncbi.nlm.nih.gov/pubmed/34438986
http://dx.doi.org/10.3390/antibiotics10080936
work_keys_str_mv AT varannaiorsolya therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT gedenoemi therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT juhaszmarkfelix therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT szakacszsolt therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT dembrovszkyfanni therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT nemethdavid therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT hegyipeter therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis
AT parniczkyandrea therapeuticapproachofchronicpseudomonasinfectionincysticfibrosisanetworkmetaanalysis